Outcome of patients with different stages of acute-on-chronic liver failure treated with artificial liver support system

被引:0
|
作者
Ma, Yuanji [1 ]
Xu, Yan [1 ]
Du, Lingyao [1 ]
Bai, Lang [1 ]
Tang, Hong [1 ]
机构
[1] Sichuan Univ, Ctr Infect Dis, West China Hosp, Chengdu, Peoples R China
关键词
acute-on-chronic liver failure; artificial liver support system; international normalized ratio of prothrombin time; timing; prognosis; PLASMA-EXCHANGE; MORTALITY; THERAPY;
D O I
10.3389/fmed.2024.1381386
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Elevated international normalized ratio of prothrombin time (PT-INR) is one of the key characteristics of acute-on-chronic liver failure (ACLF). Whether the staging of PT-INR has the ability to screen out subgroups of ACLF patients who would be more eligible for artificial liver support system (ALSS) treatment has not been studied in detail. Methods: A previous study enrolled patients receiving ALSS treatment with regional citrate anticoagulation from January 2018 to December 2019. Patients with different PT-INR intervals were retrospectively enrolled: 1.3 <= PT-INR < 1.5 (Pre-stage), 1.5 <= PT-INR < 2.0 (Early-stage), 2.0 <= PT-INR < 2.5 (Mid-stage), and PT-INR >= 2.5 (End-stage). The Cox proportional hazards models were used to estimate the association between stages of ACLF or sessions of ALSS treatment and 90 day mortality. Results: A total of 301 ACLF patients were enrolled. The 90 day mortality risk of Early-stage ACLF patients (adjusted hazard ratio (aHR) (95% confidence interval (CI)), 3.20 (1.15-8.89), p = 0.026), Mid-stage ACLF patients (3.68 (1.34-10.12), p = 0.011), and End-stage ACLF patients (12.74 (4.52-35.91), p < 0.001) were higher than that of Pre-stage ACLF patients, respectively. The 90 day mortality risk of Mid-stage ACLF patients was similar to that of Early-stage ACLF patients (1.15 (0.69-1.94), p = 0.591). The sessions of ALSS treatment was an independent protective factor (aHR (95% CI), 0.81 (0.73-0.90), p < 0.001). The 90 day mortality risk in ACLF patients received 3-5 sessions of ALSS treatment was lower than that of patients received 1-2 sessions (aHR (95% CI), 0.34 (0.20-0.60), p < 0.001), whereas the risk in patients received >= 6 sessions of ALSS treatment was similar to that of patients received 3-5 sessions (0.69 (0.43-1.11), p = 0.128). Conclusion: ACLF patients in Pre-, Early-, and Mid-stages might be more eligible for ALSS treatment. Application of 3-5 sessions of ALSS treatment might be reasonable.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Prognosis of acute-on-chronic liver failure patients treated with artificial liver support system
    Pi-Qi Zhou
    Shao-Ping Zheng
    Min Yu
    Sheng-Song He
    Zhi-Hong Weng
    [J]. World Journal of Gastroenterology, 2015, 21 (32) : 9614 - 9622
  • [2] Prognosis of acute-on-chronic liver failure patients treated with artificial liver support system
    Zhou, Pi-Qi
    Zheng, Shao-Ping
    Yu, Min
    He, Sheng-Song
    Weng, Zhi-Hong
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (32) : 9614 - 9622
  • [3] Artificial liver support in acute and acute-on-chronic liver failure
    Larsen, Fin Stolze
    [J]. CURRENT OPINION IN CRITICAL CARE, 2019, 25 (02) : 187 - 191
  • [4] Economic evaluation of the artificial liver support system MARS in patients with acute-on-chronic liver failure
    Hessel F.P.
    [J]. Cost Effectiveness and Resource Allocation, 4 (1)
  • [5] Cost-effectiveness of the artificial liver support system MARS in patients with acute-on-chronic liver failure
    Hessel, Franz P.
    Bramlage, Peter
    Wasem, Juergen
    Mitzner, Steffen R.
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (02) : 213 - 220
  • [6] A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system
    Du, Lingyao
    Ma, Yuanji
    Zhou, Shaoqun
    Chen, Fang
    Xu, Yan
    Wang, Ming
    Lei, Xuezhong
    Feng, Ping
    Tang, Hong
    Bai, Lang
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [7] A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system
    Lingyao Du
    Yuanji Ma
    Shaoqun Zhou
    Fang Chen
    Yan Xu
    Ming Wang
    Xuezhong Lei
    Ping Feng
    Hong Tang
    Lang Bai
    [J]. Scientific Reports, 11
  • [8] Artificial liver support system in hepatitis B virus-related acute-on-chronic liver failure patients
    Han, Tao
    Liu, Hua
    Zhang, Qian
    Cao, Yingying
    Ye, Qing
    Liu, Fang
    Liang, Jing
    Li, Ying
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S496 - S496
  • [9] RETRACTED: Artificial Liver Support System Combined with Liver Transplantation in the Treatment of Patients with Acute-on-Chronic Liver Failure (Retracted Article)
    Xu, Xiao
    Liu, Xiaoli
    Ling, Qi
    Wei, Qiang
    Liu, Zhikun
    Xu, Xiaowei
    Zhou, Lin
    Zhang, Min
    Wu, Jian
    Huang, Jianrong
    Sheng, Jifang
    Zheng, Shusen
    Li, Lanjuan
    [J]. PLOS ONE, 2013, 8 (03):
  • [10] Extracorporeal Liver Support and Liver Transplant for Patients with Acute-on-Chronic Liver Failure
    Li, Han
    Chen, Harvey Shi-Hsien
    Nyberg, Scott L.
    [J]. SEMINARS IN LIVER DISEASE, 2016, 36 (02) : 153 - 160